PHASE accurately predicted the NAT2 acetylation phenotype in 92 of 93 samples (99%) from genotypic data in our mixed ancestry study population, and could be used as an alternative to molecular methods to individualise isoniazid therapy in our high tuberculosis burden setting. Here, NAT2 is linked to tuberculosis.